- Home
- QURE vs FLGT Comparison
QURE vs FLGT Comparison
Compare QURE & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- FLGT
- Stock Information
- Founded
- QURE 1998
- FLGT 2011
- Country
- QURE Netherlands
- FLGT United States
- Employees
- QURE N/A
- FLGT N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- FLGT Medical Specialities
- Sector
- QURE Health Care
- FLGT Health Care
- Exchange
- QURE Nasdaq
- FLGT Nasdaq
- Market Cap
- QURE 725.4M
- FLGT 587.3M
- IPO Year
- QURE 2007
- FLGT 2016
- Fundamental
- Price
- QURE $15.21
- FLGT $18.41
- Analyst Decision
- QURE Strong Buy
- FLGT Buy
- Analyst Count
- QURE 10
- FLGT 2
- Target Price
- QURE $37.20
- FLGT $24.00
- AVG Volume (30 Days)
- QURE 1.0M
- FLGT 237.7K
- Earning Date
- QURE 07-29-2025
- FLGT 08-01-2025
- Dividend Yield
- QURE N/A
- FLGT N/A
- EPS Growth
- QURE N/A
- FLGT N/A
- EPS
- QURE N/A
- FLGT N/A
- Revenue
- QURE $20,201,000.00
- FLGT $292,448,000.00
- Revenue This Year
- QURE N/A
- FLGT $11.79
- Revenue Next Year
- QURE $278.91
- FLGT $10.45
- P/E Ratio
- QURE N/A
- FLGT N/A
- Revenue Growth
- QURE 6.30
- FLGT 1.71
- 52 Week Low
- QURE $4.45
- FLGT $14.57
- 52 Week High
- QURE $19.18
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- QURE 55.32
- FLGT 41.01
- Support Level
- QURE $13.61
- FLGT $17.50
- Resistance Level
- QURE $15.49
- FLGT $19.24
- Average True Range (ATR)
- QURE 0.81
- FLGT 0.64
- MACD
- QURE 0.08
- FLGT -0.03
- Stochastic Oscillator
- QURE 72.65
- FLGT 36.99
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.